ARS Pharmaceuticals (SPRY) Enterprise Value (2020 - 2026)
ARS Pharmaceuticals (SPRY) reported Enterprise Value of -$201.0 million for Q1 2026, up 27.11% on a YoY basis from -$158.1 million in Q1 2025, and up 17.97% sequentially from -$245.0 million in Q4 2025.
ARS Pharmaceuticals (SPRY) Enterprise Value (2020 - 2026) Analysis & Trends
ARS Pharmaceuticals (SPRY) has 7 years of Enterprise Value data on file, last reported at -$201.0 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value rose 27.11% year-over-year to -$201.0 million; the trailing twelve-month figure through Mar 2026 stood at -$201.0 million (up 27.11% YoY), and the FY2025 full-year result was -$245.0 million, up 21.98% from the prior year.
- Enterprise Value advanced to -$201.0 million in Q1 2026, from -$245.0 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$201.0 million in Q1 2026 to a low of -$314.0 million in Q4 2024.
- A 5-year average of -$250.1 million and a median of -$252.2 million in 2023 frame the typical range for Enterprise Value.
- Peak annual rise in Enterprise Value reached 32.16% in 2022, while the deepest fall reached 356.82% in 2022.
- Tracing SPRY's Enterprise Value over 5 years: stood at -$274.4 million in 2022, then advanced by 16.77% to -$228.4 million in 2023, then slumped by 37.51% to -$314.0 million in 2024, then rose by 21.98% to -$245.0 million in 2025, then increased by 17.97% to -$201.0 million in 2026.
- Business Quant data shows SPRY's Enterprise Value at -$201.0 million in Q1 2026, -$245.0 million in Q4 2025, and -$288.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | -61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.83 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -1.91 Bn |
| 10 | ARS Pharmaceuticals | 595.78 Mn | 394.81 Mn | - | -200.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -200.97 Mn |
| Dec 31, 2025 | -244.99 Mn |
| Sep 30, 2025 | -288.21 Mn |
| Jun 30, 2025 | -240.13 Mn |
| Mar 31, 2025 | -275.73 Mn |
| Dec 31, 2024 | -314.02 Mn |
| Sep 30, 2024 | -204.62 Mn |
| Jun 30, 2024 | -218.74 Mn |
| Mar 31, 2024 | -223.63 Mn |
| Dec 31, 2023 | -228.36 Mn |
| Sep 30, 2023 | -241.90 Mn |
| Jun 30, 2023 | -252.21 Mn |
| Mar 31, 2023 | -264.55 Mn |
| Dec 31, 2022 | -274.38 Mn |
| Sep 30, 2022 | -266.62 Mn |
| Jun 30, 2022 | -257.98 Mn |
| Mar 31, 2022 | -253.85 Mn |
| Dec 31, 2021 | -60.06 Mn |
| Sep 30, 2021 | -300.66 Mn |
| Jun 30, 2021 | -359.69 Mn |